Trial reportBMC anesthesiology2025
Effect of high-flow nasal cannula oxygen therapy on the postoperative atelectasis in interventional sclerotherapy: a randomized controlled trial.
Trial report in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveChildren undergoing interventional treatment for vascular malformations (VMs) can easily develop perioperative atelectasis. High-flow nasal cannula (HFNC) oxygen therapy shows the potential to reduce perioperative atelectasis. The aim of our study was to explore the potential efficacy of HFNC oxygen therapy for reducing the incidence of perioperative atelectasis in Pediatric interventional treatment for vascular malformations.
methodsThis study was a prospective randomized controlled trial with patient-blinded structure. A total of 81 pediatric patients scheduled for interventional sclerotherapy for VMs were randomly divided into three groups: the mask oxygenation group (Group M) (n = 27), the endotracheal intubation group (Group T) (n = 27), and the HFNC group (Group H) (n = 27). The incidence of atelectasis was assessed at T1 (at the end of surgery) and T2 (upon discharge from the PACU).Other intraoperative and postoperative outcomes were also evaluated.
resultsA total of 80 pediatric surgical patients were included (26 patients in Group M, 27 patients in Group T, and 27 patients in Group H). Primary outcome was at T2, significant atelectasis was observed in 17, 24, and 24 pediatric patients in Groups H, M, and T, respectively (63% vs. 88.9% vs. 92.3%; P = 0.011). The secondary outcomes were the awakening time, PAED score, incidence of agitation during awakening, and incidence of postoperative nausea and vomiting in Group M and Group H were significantly lower than those in Group T (P < 0.05).
conclusionIn summary, the use of transnasal high-flow oxygen therapy (HFNC) during DSA-guided interventional therapy for vascular malformations can reduce postoperative lung ultrasound scores (LUS) and the incidence of atelectasis in pediatric patients. General anesthesia with endotracheal intubation requires more anesthetic drugs, which may induce adverse reactions such as postoperative nausea, vomiting, and agitation in children, whereas the likelihood of such complications is reduced in children receiving HFNC. For pediatric patients at high risk of postoperative pulmonary complications, further research is needed to determine whether transnasal high-flow oxygen therapy during anesthesia maintenance can reduce the long-term risk of pulmonary complications.
trial registrationChinese Clinical Trial Registration number: ChiCTR2300078634.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.